
pmid: 23137577
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their long-term safety. Additionally, questions have also emerged regarding the association between bisphosphonates and other rare adverse events, such as esophageal cancer and atrial fibrillation. This article summarizes the current knowledge regarding the major side effects associated with the use of bisphosphonates, identifies at-risk populations for these side effects, and provides guidance for their use.
Bone Density Conservation Agents, Diphosphonates, Esophageal Neoplasms, Atrial Fibrillation, Esophagitis, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Risk Assessment
Bone Density Conservation Agents, Diphosphonates, Esophageal Neoplasms, Atrial Fibrillation, Esophagitis, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Risk Assessment
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 29 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
